Immunoreactivity for TIMP-2 is associated with a favorable prognosis in endometrial carcinoma.

Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Volumn 33, Issue 4, 2012, Pages 935-941

  Honkavuori Toivola, Maria ^a   Talvensaari Mattila, Anne ^b   Soini, Ylermi ^b   Turpeenniemi Hujanen, Taina ^b   Santala, Markku ^b  

^a UNIVERSITY OF OULU   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; ENDOMETRIUM TUMOR; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TISSUE INHIBITOR OF METALLOPROTEINASE-2; TUMOR MARKERS, BIOLOGICAL;

EID: 84867623016     PISSN: None     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0321-7     Document Type: Article

References (0)